8-K: Klotho Neurosciences Granted Nasdaq Extension to Regain Compliance

Klotho Neurosciences receives an extension from Nasdaq until August 13, 2025, to regain compliance with listing rules, subject to achieving specific milestones.

Summary

• Klotho Neurosciences, Inc. received notification from Nasdaq that the Nasdaq Hearing Panel has granted the company an extension to regain compliance with Nasdaq Listing Rules 5450(b)(2&3)(C) and 5450(b)(2)(A).
• The extension is valid until August 13, 2025, but is contingent on Klotho Neurosciences achieving scheduled milestones and notifying Nasdaq of such achievement.
• Failure to meet these milestones within the specified timeframe may result in the Panel revoking the extension.
• The initial non-compliance notices were received on August 16, 2024, due to not meeting the minimum Market Value of Publicly Held Shares (MVPHS) and minimum Market Value of Listed Securities (MVLS) requirements.
• Klotho Neurosciences was initially given until February 12, 2025, to regain compliance.
• On February 14, 2025, the company received a delisting notice from Nasdaq.
• Klotho Neurosciences appealed the delisting determination on February 21, 2025, which stayed the suspension of its securities.
• A hearing before the Panel took place on March 28, 2025.

Sentiment

Score: 5

Explanation: The news is mixed. While the extension is positive, the underlying issue of non-compliance remains a concern. The company's future depends on meeting the milestones set by Nasdaq.

Positives

• Klotho Neurosciences has been granted an extension by Nasdaq, providing more time to regain compliance with listing requirements.
• The appeal of the delisting notice was successful in obtaining a hearing and subsequent extension.

Negatives

• Klotho Neurosciences is currently not in compliance with Nasdaq's minimum Market Value of Publicly Held Shares (MVPHS) and minimum Market Value of Listed Securities (MVLS) requirements.
• The extension is conditional, and failure to meet milestones could lead to delisting.

Risks

• Failure to achieve the milestones set by Nasdaq could result in the revocation of the extension and subsequent delisting from The Nasdaq Stock Market LLC.
• Continued non-compliance with Nasdaq listing rules could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company must achieve scheduled milestones to maintain compliance and avoid delisting.

Industry Context

Many small-cap biotech companies face challenges in maintaining listing compliance, especially those with volatile stock prices or limited public float.

Stakeholder Impact

• Shareholders face the risk of delisting if the company fails to regain compliance.
• Employees' job security could be affected by the company's financial stability and listing status.

Next Steps

• Klotho Neurosciences must achieve the milestones set by the Nasdaq Hearing Panel.
• The company must notify Nasdaq of the achievement of these milestones.

Key Dates

Keywords

Nasdaq, compliance, listing rules, extension, delisting, MVPHS, MVLS, Klotho Neurosciences